Kuper Spencer G, Abramovici Adi R, Jauk Victoria C, Harper Lorie M, Biggio Joseph R, Tita Alan T
University of Alabama at Birmingham, Center for Women's Reproductive Health, Birmingham, AL.
University of Alabama at Birmingham, Center for Women's Reproductive Health, Birmingham, AL.
Am J Obstet Gynecol. 2017 Oct;217(4):476.e1-476.e6. doi: 10.1016/j.ajog.2017.05.033. Epub 2017 May 23.
Smoking during pregnancy is associated with adverse maternal and neonatal outcomes such as preterm delivery, intrauterine growth restriction, stillbirth, and low birth weight. Because smoking causes oxidative stress, some have suggested using antioxidants to counteract the effects of oxidative stress. Smokers have lower serum levels of omega-3 fatty acids, an important antioxidant, and thus, investigating whether omega-3 supplementation in smokers reduces adverse maternal and neonatal outcomes represents an important area of research.
To investigate whether the antioxidant effect of omega-3 fatty acid supplementation on the incidence of adverse pregnancy outcomes differs between smokers and nonsmokers.
Secondary analysis of a multicenter randomized controlled trial of omega-3 supplementation for preterm delivery prevention in women with a singleton pregnancy and a history of a previous singleton spontaneous preterm delivery. Subjects were randomized to begin omega-3 or placebo before 22 weeks, which was continued until delivery. All women received 17 alpha-hydroxyprogesterone caproate intramuscularly weekly beginning between 16 and 20 weeks of gestation and continued until 36 weeks of gestation or delivery, whichever occurred first. The primary outcome was spontaneous preterm delivery. Secondary outcomes were indicated preterm delivery, any preterm delivery (spontaneous and indicated), pregnancy-associated hypertension (gestational hypertension and preeclampsia), a neonatal composite (retinopathy of prematurity, intraventricular hemorrhage grade III or IV, patent ductus arteriosus, necrotizing enterocolitis, sepsis, respiratory morbidity, or perinatal death), low birth weight (<2500 g), small for gestational age (less than the 10th percentile), and neonatal intensive care unit or intermediate nursery admission. The study population was stratified into smokers and nonsmokers, and the incidence of each outcome was compared by omega-3 supplementation versus placebo in each subgroup. Zelen tests were performed to test for homogeneity of effect in smokers and nonsmokers.
Of 851 subjects included in the analysis, 136 (16%) smoked. Baseline characteristics between omega-3 and placebo groups did not differ in smokers or nonsmokers. Omega-3 supplementation was associated with a lower risk of spontaneous preterm delivery in smokers (relative risk, 0.56, 95% confidence interval, 0.36-0.87) but not in nonsmokers (relative risk 1.04, 95% confidence interval 0.84-1.29); P value for interaction = 0.013. Low birth weight was also less frequent in smokers receiving omega-3 supplementation (relative risk 0.57, 95% confidence interval 0.36-0.90) compared with nonsmokers (relative risk 0.93, 95% confidence interval 0.71-1.24); P value for interaction = 0.047. The effect on other secondary outcomes did not differ significantly between smokers and nonsmokers.
Omega-3 supplementation in smokers may have a protective effect against recurrent spontaneous preterm delivery and low birth weight.
孕期吸烟与不良的母婴结局相关,如早产、胎儿宫内生长受限、死产和低出生体重。由于吸烟会导致氧化应激,一些人建议使用抗氧化剂来抵消氧化应激的影响。吸烟者血清中的ω-3脂肪酸(一种重要的抗氧化剂)水平较低,因此,研究对吸烟者补充ω-3是否能减少不良的母婴结局是一个重要的研究领域。
研究ω-3脂肪酸补充剂对不良妊娠结局发生率的抗氧化作用在吸烟者和非吸烟者中是否存在差异。
一项多中心随机对照试验的二次分析,该试验旨在对单胎妊娠且有单胎自发性早产史的女性补充ω-3以预防早产。受试者在孕22周前随机开始服用ω-3或安慰剂,并持续至分娩。所有女性在妊娠16至20周之间开始每周肌肉注射17α-羟孕酮己酸酯,持续至妊娠36周或分娩,以先发生者为准。主要结局是自发性早产。次要结局包括医源性早产、任何早产(自发性和医源性)、妊娠相关高血压(妊娠期高血压和先兆子痫)、新生儿综合指标(早产儿视网膜病变、III或IV级脑室内出血、动脉导管未闭、坏死性小肠结肠炎、败血症、呼吸系统疾病或围产期死亡)、低出生体重(<2500g)、小于胎龄儿(低于第10百分位数)以及新生儿重症监护病房或中级护理病房收治情况。研究人群被分为吸烟者和非吸烟者,比较每个亚组中补充ω-3与安慰剂后各结局的发生率。进行Zelen检验以检测吸烟者和非吸烟者中效应的同质性。
纳入分析的851名受试者中,136名(16%)吸烟。吸烟者和非吸烟者中,ω-3组和安慰剂组的基线特征无差异。补充ω-3与吸烟者自发性早产风险较低相关(相对风险为0.56,95%置信区间为0.36 - 0.87),但与非吸烟者无关(相对风险为1.04,95%置信区间为0.84 - 1.29);交互作用P值 = 0.013。与非吸烟者(相对风险为0.93,95%置信区间为0.71 - 1.24)相比,接受ω-3补充剂的吸烟者中低出生体重的发生率也较低(相对风险为0.57,95%置信区间为0.36 - 0.90);交互作用P值 = 0.047。对其他次要结局的影响在吸烟者和非吸烟者之间无显著差异。
对吸烟者补充ω-3可能对复发性自发性早产和低出生体重具有保护作用。